Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

LGMD2E patients risk developing dilated cardiomyopathy.

M Fanin1, P Melacini, C Boito

  • 1Department of Neurological and Psychiatric Sciences, University of Padova, via Giustiniani 5, 35128 Padova, Italy. marina.fanin@unipd.it

Neuromuscular Disorders : NMD
|July 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dysferlinopathy course and sportive activity: clues for possible treatment.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology·2011
Same author

Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.

Journal of neurology·2011
Same author

Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency.

Clinical genetics·2011
Same author

Aberrant splicing and expression of the non muscle myosin heavy-chain gene MYH14 in DM1 muscle tissues.

Neurobiology of disease·2011
Same author

Observation of the decay B- → D(s)((*)+) K- ℓ- ν(ℓ).

Physical review letters·2011
Same author

Search for production of invisible final states in single-photon decays of Υ(1S).

Physical review letters·2011

Mutations in the beta-sarcoglycan gene cause limb-girdle muscular dystrophy. This study found significant cardiac involvement in 50% of patients, highlighting the need for cardiac monitoring in beta-sarcoglycanopathy.

Area of Science:

  • Genetics
  • Neurology
  • Cardiology

Background:

  • Sarcoglycan gene mutations are linked to limb-girdle muscular dystrophies (LGMD).
  • Despite sarcoglycan expression in cardiac muscle, cardiomyopathy is rarely documented in sarcoglycanopathies.
  • Beta-sarcoglycanopathy (LGMD2E) is a specific form of LGMD with potential cardiac implications.

Purpose of the Study:

  • To investigate the prevalence and characteristics of cardiac involvement in patients with beta-sarcoglycanopathy.
  • To analyze skeletal muscle sarcoglycan expression in relation to clinical presentation.
  • To assess the risk of cardiomyopathy in LGMD2E patients.

Main Methods:

  • Studied six patients diagnosed with beta-sarcoglycanopathy.
  • Performed immunohistochemical and immunoblot analysis on skeletal muscle biopsies from five patients.

Related Experiment Videos

  • Conducted non-invasive cardiac examinations to assess cardiac function.

    • Main Results:

    • Skeletal muscle biopsies showed complete loss or marked reduction of all sarcoglycans in affected patients.
    • Three out of six patients (50%) exhibited cardiac involvement.
    • Cardiac involvement ranged from severe dilated cardiomyopathy to moderate cardiac dysfunction, with one patient presenting a novel mutation.

    Conclusions:

    • Beta-sarcoglycanopathy frequently involves cardiac muscle, with a 50% prevalence of cardiomyopathy in the studied cohort.
    • Early and regular cardiac monitoring is crucial for patients with beta-sarcoglycanopathy due to the high risk of developing cardiomyopathy.
    • Further research is needed to understand the genetic and molecular mechanisms underlying cardiac involvement in LGMD2E.